ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib

Sorafenib represents the standard of care for advanced hepatocellular carcinoma (HCC), even though a large number of patients have reported limited efficacy. The aim of the present study was to evaluate the prognostic value of single-nucleotide polymorphisms on angiopoietin-2 (ANGPT2) and endothelia...

Descripción completa

Detalles Bibliográficos
Autores principales: Marisi, Giorgia, Petracci, Elisabetta, Raimondi, Francesco, Faloppi, Luca, Foschi, Francesco Giuseppe, Lauletta, Gianfranco, Iavarone, Massimo, Canale, Matteo, Valgiusti, Martina, Neri, Luca Maria, Ulivi, Paola, Orsi, Giulia, Rovesti, Giulia, Vukotic, Ranka, Conti, Fabio, Cucchetti, Alessandro, Ercolani, Giorgio, Andrikou, Kalliopi, Cascinu, Stefano, Scartozzi, Mario, Casadei-Gardini, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679015/
https://www.ncbi.nlm.nih.gov/pubmed/31330833
http://dx.doi.org/10.3390/cancers11071023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679015/
https://www.ncbi.nlm.nih.gov/pubmed/31330833
http://dx.doi.org/10.3390/cancers11071023

Ejemplares similares